Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1998-05-21
2000-06-20
Spear, James M.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424457, 514290, 514778, A61K 922, A61K 952
Patent
active
060775378
ABSTRACT:
The present invention relates to methods of using and compositions containing acrivastine which provide antihistaminic therapeutic benefits while minimizing undesirable central nervous system side effects. According to the present invention, the plasma concentration-response curve for acrivastine's sedative side effects is steeper than that of the plasma concentration-response curve for its antihistamine activity. Accordingly, when the peak blood plasma level of acrivastine is maintained within the levels provided by the present invention composition, the central nervous side effects are minimized while the antihistaminic effects are optimized.
REFERENCES:
patent: 4783465 (1988-11-01), Sunshine et al.
patent: 4829064 (1989-05-01), Sunshine et al.
patent: 4871733 (1989-10-01), Sunshine et al.
patent: 4954350 (1990-09-01), Jones et al.
patent: 4975426 (1990-12-01), Sunshine et al.
patent: 5370880 (1994-12-01), Jones et al.
patent: 5451409 (1995-09-01), Rencher et al.
patent: 5456921 (1995-10-01), Mateescu et al.
patent: 5603956 (1997-02-01), Mateescu et al.
patent: 5616343 (1997-04-01), Cartilier et al.
patent: 5645858 (1997-07-01), Kotwal et al.
Pharmacokinetics of Acrivastine, A new H.sub.1 -Antagonist, Following Ascending Doses. N. S. Jallad, D. C. Garg, R. J. Fleck, S. H. Poe, M. R. Blum, J.W.A. Findlay, S.H.T. Liao, M. F. Frosolono, and D. J. Weidler, J. Clin. Pharaceutical; 985,25:632 (abstract), 1985.
Acrivastine. A Review of its Pharmacological Properties and Therapeutic Efficacy in Allergic Rhinitis, Urticaria and Related Disorders. Rex N. Brogden and Donna McTavish. Drugs 41 (6) 1991:pp. 927-540.
Pharmacodynamic and Pharmacokinetics of BW 825C: A New Antihistamine. A. F. Cohen, M. J. Hamilton, S. H. T. Liao, J.W. A. Findlay, and A. W. Peck. Eur J. Clin. Pharmacol (1985) 28: p. 197-204.
Pharmacokinetics of Acrivastine after Oral and Colonic Administration. Ramadas Balasubramanian, Kenneth B. Klein, A. Wayne Pittman, Sam H. T. Liao, John W. A. Findlay, and M. F. Frosolono J. Clin. Pharmacol (1989). 29: p. 444-447.
Development and application of a pharmacokinetics simulation program for oral controlled release dosage forms--DIPS. H. P. Jones, R. Clements, D. J. Hearn, M. J. Gamlen. International Journal of Pharmaceutics 104 (1994): pp. 253-270.
Booth Anthony
Dickstein Harvey
Koup Jeffrey R.
Federman Evan J.
Spear James M.
Warner-Lambert & Company
LandOfFree
Non-sedating acrivastine product does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-sedating acrivastine product, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-sedating acrivastine product will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1850027